As of 3:59pm ET
| +0.10 / +0.95%|
Sucampo Pharmaceuticals, Inc. is a biopharmaceutical company, which is engaged in developing, identifying, acquiring and bringing medicines that meet unmet medical needs. It focuses on gastroenterology, ophthalmology, and oncology-related disorders. The company's product pipeline includes AMITIZA for the treatment of chronic idiopathic constipation in adults; irritable bowel syndrome with constipation in adult women; opioid-induced constipation in patients with chronic non-cancer pain; chronic constipation; and pediatric functional constipation. Its product pipeline also consists of Unoprostone Isopropyl, which is in Phase III trial for the treatment of retinitis pigmentosa and in pre-clinical stage for the treatment of geographic atrophy; and Cobiprostone that has completed Phase Ib trial for the treatment of oral mucositis, as well as in Phase II trial for the treatment of non-erosive reflux diseases. Sucampo Pharmaceuticals was founded by Dr. Ryuji Ueno and Dr. Sachiko Kuno on December 5, 1996 and is headquartered in Bethesda, MD.
|Peter S. Greenleaf||Chairman & Chief Executive Officer|
|Peter P. Pfreundschuh||Chief Financial Officer|
|Peter Lichtlen||Chief Medical Officer|
|Matthew Maxwell Donley||EVP-Human Resources & Information Technology|
|Peter Alec Kiener||Chief Scientific Officer|